CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the 8th Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential ...

Shares of Foghorn Therapeutics Inc. (FHTX) have gained 23.3% over the past four weeks to close the last trading session at $5.02, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $11.71 indicates a potential upside of 133.3%.The mean estimate comprises seven short-term price targets with a standard deviation of $2.06. While the lowest estimate of $9.00 indicates a 79.3% increase ...

Summary of Foghorn Therapeutics Conference Call Company Overview - **Company**: Foghorn Therapeutics (NasdaqGM:FHTX) - **Industry**: Clinical-stage oncology focused on chromatin biology - **Key Focus**: Regulating gene expression through drug discovery targeting previously undrugged proteins [3][4] Core Programs and Partnerships - **Main Compound**: Partnership with Eli Lilly focusing on SMARCA2, established with a deal worth approximately $300 million upfront and $80 million in equity [4][9] - **Current Status**: In a 50/50 cost-sharing phase for the SMARCA2 program, with a decision on dose expansion expected in the first half of 2026 [9][13] - **Other Proprietary Programs**: Targets include CBP, EP300, and ARID, with ongoing development towards IND submissions over the next 12-18 months [4][10] Drug Discovery and Development - **Unique Platform**: Foghorn has developed a platform to study large protein assemblies, enabling selective drugging of challenging targets like SMARCA2 and SMARCA4 [6][8] - **Challenges**: Historically, finding selective drugs for SMARCA2 and SMARCA4 has been difficult due to their high similarity (90% identical) [8][10] - **Efficacy Benchmarks**: For SMARCA4 mutant non-small cell lung cancer, the response rate is significantly lower (20%) compared to wild-type patients (40+%) [15][16] Clinical Insights - **Current Trials**: The SMARCA2 inhibitor (FHD-909) is in a phase one dose escalation study targeting patients with SMARCA4 mutations [12][13] - **Expected Outcomes**: Aiming for a response rate of at least 15% in the fourth-line setting, with plans to move into frontline settings based on preclinical data [17][20] Competitive Landscape - **Resistance Mechanisms**: No known resistance mechanisms for SMARCA2 inhibitors or degraders have been identified yet [21] - **Screening Process**: SMARCA4 mutations are routinely screened in major cancer centers, facilitating patient enrollment in clinical trials [23] Future Directions - **Combination Therapies**: Plans to explore combinations with pembrolizumab and chemotherapy for enhanced efficacy in SMARCA4 mutant patients [24][25] - **Pipeline Development**: Focus on multiple myeloma for EP300 degraders, with IND-enabling studies expected by late 2026 [29][30] Financial Position - **Cash Reserves**: As of Q3, Foghorn has $180 million, projected to last into early 2028, covering ongoing programs and potential future financing needs [39] Strategic Partnerships - **Partnership Philosophy**: Foghorn is open to partnerships for proprietary programs, emphasizing the need for strategic capabilities that small biotechs may lack [36][37] Conclusion - **Outlook**: Foghorn Therapeutics is positioned for significant developments in oncology, particularly with its innovative approach to chromatin biology and strategic partnerships, while maintaining a solid financial foundation for future growth [39][40]

Summary of Foghorn Therapeutics FY Conference Call Company Overview - **Company**: Foghorn Therapeutics (NasdaqGM:FHTX) - **Focus**: Targeting the chromatin regulatory system and the BAF complex, primarily in oncology [2][3] Industry Insights - **Oncology Relevance**: Approximately 50% of cancers have dependencies or mutations related to chromatin regulation, highlighting the importance of this area in cancer biology [2] - **Targeting Challenges**: The similarity between proteins in the BAF complex (e.g., SMARCA2 and SMARCA4) complicates selective targeting due to their 90%-95% similarity [3][4] Key Programs and Developments SMARCA2 Program - **Scientific Rationale**: SMARCA2 is targeted due to its synthetic-lethal relationship with SMARCA4, where loss of SMARCA4 increases dependency on SMARCA2 in cancer cells [6][7] - **Clinical Data**: Patients with SMARCA4 mutations show significantly worse prognosis in non-small cell lung cancer, with response rates dropping from approximately 40% to 20% [7] - **Market Opportunity**: In the U.S., about 22,000 non-small cell lung cancer patients have SMARCA4 mutations, with an estimated 11,000-17,000 potentially having loss of function [8] Clinical Trials - **Current Status**: The SMARCA2 inhibitor FHD-909 is in phase one trials, with ongoing dose escalation and no maximum tolerated dose reached yet [16][17] - **Study Design**: The trial includes various cancer histologies with a focus on non-small cell lung cancer patients with SMARCA4 mutations [15] - **Expected Outcomes**: Anticipation of a go/no-go decision for dose expansion in the first half of 2026 [16] CBP and EP300 Programs - **Mechanism**: CBP and EP300 are sister proteins involved in histone acetylation, with challenges in dual inhibition leading to myelosuppressive effects [21][22] - **Commercial Opportunity**: Targeting CBP could address approximately 20,000-25,000 patients with specific mutations, while EP300 shows potential in hematological malignancies [23][24] ARID1B Program - **Target Validation**: ARID1B is a highly mutated target in cancer, with Foghorn being the only company to develop selective binders for this target [27][28] - **Development Status**: The program is in hit-to-lead stage, with in vivo proof of concept expected in 2026 [29] Additional Insights - **Combination Studies**: The company recognizes the importance of combination therapies in oncology and plans to explore both monotherapy and combination regimens in future studies [18][19] - **Clinical Risks**: Acknowledgment of the risks associated with being first to market, particularly in the context of the SMARCA2 program [9][10] Conclusion Foghorn Therapeutics is positioned in a promising niche within oncology, focusing on challenging targets related to chromatin regulation. The company is advancing several innovative programs, particularly in SMARCA2, CBP, and EP300, with significant market opportunities and ongoing clinical trials that could lead to impactful treatments for cancer patients.

Core Insights - Top Wall Street analysts have revised their outlook on several prominent stocks, indicating a shift in market sentiment and potential investment opportunities [1] Group 1 - Analysts have made changes to ratings, including upgrades, downgrades, and initiations for various stocks [1] - There is a specific mention of AARD stock, suggesting it may be a focus for potential buyers based on analyst opinions [1]

Group 1: Earnings Performance - Foghorn Therapeutics Inc. reported a quarterly loss of $0.25 per share, better than the Zacks Consensus Estimate of a loss of $0.31, representing an earnings surprise of +19.35% [1] - The company posted revenues of $8.15 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.12% and showing an increase from $7.81 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates once [2] Group 2: Stock Performance and Outlook - Foghorn Therapeutics shares have declined approximately 25.2% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $9.7 million, and for the current fiscal year, it is -$1.18 on revenues of $31.3 million [7] - The estimate revisions trend for Foghorn Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which Foghorn Therapeutics belongs, is currently in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q _____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39634 ______________________ Foghorn Therapeutics ...

Financial Performance - Collaboration revenue increased to $8.2 million for Q3 2025, up from $7.8 million in Q3 2024, driven by advancements in programs under the Lilly Collaboration Agreement[14] - Net loss for Q3 2025 was $15.8 million, compared to a net loss of $19.1 million in Q3 2024, reflecting improved financial performance[18] - Total operating expenses for Q3 2025 were $26.7 million, down from $31.7 million in Q3 2024[22] - General and administrative expenses were $6.7 million for Q3 2025, down from $7.0 million in Q3 2024, primarily due to lower facilities and IT-related expenses[18] - Research and development expenses decreased to $20.0 million in Q3 2025 from $24.7 million in Q3 2024, attributed to reduced costs in FHD-286 and personnel-related expenses[14] - As of September 30, 2025, the company had $180.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2028[18] Research and Development - FHD-909 is in a Phase 1 dose escalation trial targeting SMARCA4-mutated cancers, with non-small cell lung cancer (NSCLC) as the primary focus[1] - The Selective CBP degrader program is advancing towards IND readiness in 2026, with promising preclinical data for ER+ breast cancer[7] - The Selective ARID1B degrader program is progressing towards in vivo proof-of-concept in 2026, targeting up to 5% of solid tumors[9] Collaboration - The company is collaborating with Lilly under a 50/50 co-development and co-commercialization agreement for its selective SMARCA2 oncology program[4]

Core Insights - Foghorn Therapeutics is advancing its clinical programs, particularly FHD-909, a first-in-class oral SMARCA2 selective inhibitor, in a Phase 1 trial targeting SMARCA4-mutated cancers, primarily non-small cell lung cancer (NSCLC) [1][2][3] - The company is developing several selective degrader programs, including Selective CBP, EP300, and ARID1B degraders, with promising preclinical data indicating robust anti-tumor activity and favorable tolerability [2][6][7][8] - Foghorn has a strong financial position with $180.3 million in cash and equivalents as of September 30, 2025, providing a cash runway into 2028 [1][19] FHD-909 Program - FHD-909 is designed to selectively inhibit SMARCA2, showing significant anti-tumor activity in preclinical models of SMARCA4-mutant lung tumors [3][14] - The ongoing Phase 1 trial is progressing well, with enrollment on track and preclinical data supporting its combination with standard therapies [4][2] Selective Degrader Programs - The Selective CBP degrader is entering non-GLP toxicology studies with potential applications in EP300-mutant cancers and ER+ breast cancer, aiming for IND readiness in 2026 [1][12] - The Selective EP300 degrader is showing broad efficacy across hematological malignancies, with IND-enabling studies expected in 2026 [1][7][12] - The Selective ARID1B degrader is advancing towards in vivo proof of concept in 2026, targeting ARID1A-mutated cancers, which represent up to 5% of solid tumors [1][8][13] Financial Performance - Collaboration revenue increased to $8.2 million for Q3 2025, up from $7.8 million in Q3 2024, driven by advancements in programs under the Lilly collaboration [19] - Research and development expenses decreased to $20.0 million in Q3 2025 from $24.7 million in Q3 2024, attributed to reduced costs in various areas [19] - The net loss for Q3 2025 was $15.8 million, an improvement from a net loss of $19.1 million in the same quarter of the previous year [19][22] Leadership Update - The Chief Financial Officer, Kristian Humer, will be leaving the company, with a search for a successor already underway [10]

Core Viewpoint - The conference call focuses on Foghorn's proprietary programs, particularly the selective ARID1B degrader, along with updates on other programs like selective CBP and EP300 degraders [2][4]. Group 1: Company Overview - Karin Hellsvik, Vice President of Investor Relations and Corporate Affairs, leads the call and emphasizes the focus on Foghorn's selective ARID1B degrader and other proprietary programs [2]. - Adrian Gottschalk, President and CEO, will provide an overview of the company's recent progress [4]. Group 2: Pipeline Updates - The call will include updates on the progress of Foghorn's proprietary pipeline programs, specifically ARID1B, CBP, and EP300, along with new data presented [4].